Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIO-RAD LABORATORIES, INC. Director's Dealing 2014

Nov 12, 2014

30786_dirs_2014-11-12_78def631-acf1-4109-853b-7d8cd6392fef.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO RAD LABORATORIES INC (BIO, BIOB)
CIK: 0000012208
Period of Report: 2014-11-11

Reporting Person: STARK JAMES R (VP, Corporate Controller)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2014-11-11 Bio-Rad A Common Stock M 300 $62.47 Acquired 4257 Direct
2014-11-11 Bio-Rad A Common Stock S 300 $112.23 Disposed 3957 Direct
2014-11-11 Bio-Rad A Common Stock S 3357 $112.56 Disposed 600 Direct
2014-11-11 Bio-Rad A Common Stock S 600 $113.04 Disposed 0 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2014-11-11 Non-Qualified Stock Option (right to buy) $62.47 M 300 Disposed 2016-04-03 Bio-Rad A Common Stock (300) Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.86 to $112.83, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.94 to $113.09, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The option vested in five equal annual installments beginning on April 3, 2007.